Abstract 1135P
Background
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cancer of the skin, characterized by a high propensity for metastasis and a dismal prognosis particularly for advanced tumor stages. Immune-checkpoint blockade (ICB) is effective in MCC, but 60% of patients show primary or acquired resistance. Predictive biomarkers for the risk of metastasis and response to ICB are lacking. We studied the tumor microenvironment (TME) of 60 MCC patients to identify molecular mechanisms associated with response to ICB and profile the temporal dynamics occurring during tumor progression.
Methods
We collected 115 tissue biopsies from this MCC cohort with detailed clinical documentation and longitudinal follow-up and profiled the TME with high-plex imaging and matched bulk RNAseq that was collected from consecutive sections using laser-capture microdissection. We integrated clinical and molecular data and explored biomarkers using a lasso regressed CoxPH model.
Results
Our multi-modal data integration framework identified Merkel cell polyomavirus positivity, the abundance of CD8+ T cells and PD-L1+ macrophages as independent determinants of metastasis-free survival (DMFS), while the enrichment of cancer-associated fibroblasts at the tumor boundary correlated with distant metastasis. Response to ICB was correlated with the presence of central memory T cells (TCM), and Follicle-like cellular neighborhoods as well as a PD-L1+ tumor phenotype, that associated with an inflammatory macrophage signature (CXCL9, CXCL10, CXCL13) specifically at the tumor invasive front. By contrast, ICB failure associated with a cancer-stem phenotype (SOX2, NELL) and the downregulation of type-II interferon signaling (STAT1, JAK1). Last, we identified that exacerbation of T cell exhaustion, loss of TCM and inflammatory macrophages are critical elements of MCC evolutionary progression.
Conclusions
We demonstrate that high dimensional imaging of the MCC TME provides a framework to interrogate cellular interactions and tissue architecture in-situ at single-cell resolution. This framework enabled to identify genomic and phenotypic correlates for distant metastasis and response to ICB and map evolutionary changes during tumor progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Deutsche Forschungsgemeinschaft.
Disclosure
G. Nolan: Financial Interests, Personal, Stocks or ownership: Akoya Bio. All other authors have declared no conflicts of interest.
Resources from the same session
1221P - Stereotactic ablative radiotherapy in combination with nivolumab for early stage operable non-small cell lung cancer: A phase II study
Presenter: Gustavo Schvartsman
Session: Poster session 04
1222P - Predicting pathological complete response to neoadjuvant chemoimmunotherapy in resected NSCLC with radiomic signatures
Presenter: Mohammadhadi Khorrami
Session: Poster session 04
Resources:
Abstract
1223P - Sex specific efficacy and safety outcomes in operable stage III non-small cell lung cancer (NSCLC): Pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
Presenter: Lorenz Frehner
Session: Poster session 04
1224P - Evaluation of safety and feasibility of adjuvant chemotherapy in elderly patients with primary non-small cell lung cancer
Presenter: Alice MOGENET
Session: Poster session 04
1225P - Perioperative serplulimab and chemotherapy in patients with resectable squamous non-small cell lung cancer: An open-label, single-arm, phase II trial
Presenter: Haiquan Chen
Session: Poster session 04
1226P - Predictive value of circulating tumor DNA (ctDNA) before and shortly after curative treatment in early stage non-small cell lung cancer (NSCLC), and exploration of (pre-)analytical factors
Presenter: Michel van den Heuvel
Session: Poster session 04
1227P - Update on the analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1
Presenter: Maria Sereno
Session: Poster session 04
1228P - Association between air pollution and frequency of driver mutation among a Hispanic population with lung cancer
Presenter: Mateo Tamayo
Session: Poster session 04
Resources:
Abstract
1229P - Precision patient selection for postoperative therapy in resectable NSCLC: A comprehensive postoperative-risk model incorporating genetic and histological features
Presenter: Yuanzi Ye
Session: Poster session 04
1230P - Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective study
Presenter: Mariano Provencio Pulla
Session: Poster session 04